<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771483</url>
  </required_header>
  <id_info>
    <org_study_id>RESP/16/44</org_study_id>
    <nct_id>NCT02771483</nct_id>
  </id_info>
  <brief_title>Improving the Diagnosis and Prognostication of GCA Through the Novel Use of PET Scan and Immune Biomarkers</brief_title>
  <official_title>Improving the Diagnosis and Prognostication of Giant Cell Arteritis Through the Novel Use of Positron Emission Tomography (PET), Microbiological and Immune Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal North Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal North Shore Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant cell arteritis (GCA) is a medium to large vessel vasculitis with a predilection for
      the superficial cranial and intrathoracic arteries. Diagnosing the condition and predicting
      which patients will develop large vessel complications remains a challenge. There are
      limitations with temporal artery biopsy, magnetic resonance angiography and ultrasound of
      temporal arteries and American College of Rheumatology classification criteria.

      Positron emission tomography (PET) has been shown to be a useful modality in detecting
      inflammation in large intra-thoracic vessels but previously has not been able to accurately
      detect FDG uptake in the superficial cranial arteries due to poor spatial resolution. Newer
      scanners can perform finer cuts of the head and can detect uptake in these arteries.

      This study has three main components:

        1. Cross sectional study assessing the accuracy of PET uptake in the superficial cranial
           and intrathoracic arteries of suspected GCA patients for the diagnosis of GCA

        2. Cohort study assessing the prognostic implication of FDG aortic uptake on aortic
           diameter at 24 months

        3. Cohort study assessing the Th1 and Th17 cytokine profile in patients with and without
           FDG PET uptake at 0, 6 and 24 months
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of FDG uptake in the superficial cranial or intrathoracic arteries for the diagnosis of temporal artery biopsy proven GCA amongst patients with suspected GCA</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in aortic diameter at 24 months between patients with and without PET scan aortic uptake at time 0.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Th1 and Th17 axis cytokines in patients with and without thoracic large vessel PET uptake at 0, 6 and 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of varicella zoster virus antigen and DNA in temporal artery biopsy GCA specimens</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of acute varicella zoster IgM serology positivity in biopsy confirmed GCA patients</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in combined vascular events between GCA patients with and without thoracic large vessel PET uptake at 0, 6 and 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in temporal artery histology between GCA patients with and without thoracic large vessel PET uptake at 0 months</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in temporal artery histology between GCA patients with and without temporal artery PET uptake at 0 months</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Suspected GCA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Case controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Temporal artery specimens Serology
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Suspected GCA
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatologist, neurologist or ophthalmologist suspect diagnosis of GCA

          -  Age &gt; 50

          -  Meet at least 2 of 1990 American College of Rheumatology classification criteria for
             GCA

               1. Age &gt;= 50

               2. ESR &gt;= 50

               3. New onset localised headache

               4. Temporal artery abnormality (tenderness or decreased pulsation)

               5. Positive biopsy (will not be available at time of enrolment)

        Exclusion Criteria:

          -  Corticosteroid therapy for &gt; 72 hours before first PET scan

          -  Prolonged corticosteroid therapy (&gt; 1 week) for another indication in past 6 months

          -  History of vasculitis or connective tissue disease

          -  Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony M Sammel, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal North Shore Hospital, St Leonards, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony M Sammel, MBBS</last_name>
    <phone>+61294631887</phone>
    <phone_ext>Mobile</phone_ext>
    <email>tsammel@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodger Laurent, MD</last_name>
    <phone>+61294631887</phone>
    <phone_ext>Mobile</phone_ext>
    <email>rlaurent@med.usyd.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony M Sammel, MBBS</last_name>
      <phone>+61294631887</phone>
      <phone_ext>Mobile</phone_ext>
      <email>tsammel@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rodger Laurent, MD</last_name>
      <phone>+61294631887</phone>
      <phone_ext>Mobile</phone_ext>
      <email>rlaurent@med.usyd.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony M Sammel, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodger Laurent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leslie Schrieber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Roach, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dale Bailey, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoff Schembri, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Janssen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 15, 2016</lastchanged_date>
  <firstreceived_date>May 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal North Shore Hospital</investigator_affiliation>
    <investigator_full_name>Anthony Sammel</investigator_full_name>
    <investigator_title>Rheumatology fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
